``This morning Merck is announcing a voluntary worldwide withdrawal of Vioxx,'' Gilmartin began.
The FDA's own study of the Vioxx safety issue has become mired in controversy.
Celebrex and Vioxx have become household names in recent years.
``I was stunned,'' said Kim who had expected positive results.
"He did so voluntarily," the agency said.
Galson said that his agency met often with Merck to discuss earlier troubling Vioxx studies, and said that ``we insisted that we needed more information about the cardiovascular risks.''
By contrast, Vioxx made $2.5 billion for Merck last year.
The company was already facing two class action lawsuits alleging patient harm from Vioxx.
